Skip to main content
Information for...
Please select
General Use
Patients or Carers
Health Care Professionals in the US
Health Care Professionals outside the US
Journalists
Jobseekers
Press
Contact
Global sites
About Us
Corporate Profile
Our Company
Vision & Values
History
Diversity & Inclusion
Ethics & Compliance
Sustainability
Making More Health
Access to Healthcare
Press
Press Releases
Image Mediapool
Events & Initiatives
Media Contacts
Annual Press Conference
Global Activities
Europe
North America
South America
Asia
Africa
Australasia
Products
Innovation
Research & Development
Research Approach
Research Beyond Borders
Drug Discovery
Open Innovation
Clinical Trials
Overview
Therapeutic Areas
CardioMetabolic
CNS
Immunology & Respiratory
Oncology
Boehringer Ingelheim Venture Fund
Partnering
Our Approach
Overview
What We Offer
Partnering Interests
Overview
How We Engage
Overview
News & Communications
Press Releases
Events
Partnering Newsletter
Contact Us
Human Pharma
Cardiovascular
Stroke Prevention
Acute Ischaemic Stroke
DVT/PE
Reversal of Anti-coagulation
Myocardial Infarction
Hypertension
Oncology
Lung Cancer
Respiratory
Asthma
COPD
IPF
Scleroderma
Central Nervous System
Overview
Metabolic Diseases
Diabetes
IntroDia
Immunology
Overview
Animal Health
Home
About Animal Health Business Unit
Livestock
Companion Animals
Our Responsibility
Press Releases
Biopharma
Careers
Search form
Search
Aggrenox
®
Prevention of stroke following an initial first stroke, or transient ischaemic attacks (TIA).
Indications
Secondary prevention of stroke or transient ischaemic attacks (TIA)
Brand Names
Aggrenox
®
Asasantin
®
Asasantin
®
Retard
Active ingredients
dipyridamole,
acetylsalicylic acid
